These findings suggest that BU peptide can inhibit GRP-mediated activation of the PI3K/Akt and MAPK/ERK pathways in SCLC cells, potentially by interfering with GRP receptor signalling. This evidence concerns the gene AKT1 and small cell lung carcinoma.